Literature DB >> 2647817

Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: effects on infarct size and left ventricular function.

J P Bassand1, J Machecourt, J Cassagnes, T Anguenot, R Lusson, E Borel, P Peycelon, E Wolf, D Ducellier.   

Abstract

Two hundred thirty-one patients with a first acute myocardial infarction were randomly allocated within 5 h after the onset of symptoms either to treatment with anisoylated plasminogen streptokinase activator complex (APSAC), 30 U over 5 min, or to conventional heparin therapy, 5,000 IU in a bolus injection. Heparin was reintroduced in both groups 4 h after initial therapy at a dosage of 500 IU/kg per day. One hundred twelve patients received APSAC and 119 received heparin within a mean period of 188 +/- 62 min after the onset of symptoms. Both groups were similar in age, location of the acute myocardial infarction, Killip functional class and time of randomization. Elective coronary arteriography was performed on an average of 4 +/- 1.2 days after initial therapy. Follow-up radionuclide angiography and thallium-201 single photon emission computed tomography were performed before hospital discharge. Infarct size was estimated from single photon emission computed tomography and expressed as a percent of total myocardial volume. The patency rate of the infarct-related artery was 77% in the APSAC group and 36% in the heparin group (p less than 0.001). Left ventricular ejection fraction determined from contrast angiography was significantly higher in the APSAC group than in the heparin group. This was true for the entire study group (0.53 +/- 0.13 versus 0.47 +/- 0.12; p = 0.002) as well as for the subgroups of patients with anterior and inferior wall infarction (0.47 +/- 0.13 versus 0.40 +/- 0.11; p = 0.04 and 0.56 +/- 0.10 versus 0.51 +/- 0.11; p = 0.02, respectively). At 3 weeks, the difference remained significant for the anterior myocardial infarction subgroup. A significant 31% reduction in infarct size was found in the APSAC group (33% for the anterior infarction subgroup [p less than 0.05] and 16% for the inferior infarction subgroup [p = NS]). A close inverse relation was found between the values of left ventricular ejection fraction and infarct size (r = -0.73, p less than 0.01). By the end of a 3 week follow-up period, seven APSAC-treated patients and six heparin-treated patients had died. In conclusion, the early infusion of APSAC in acute myocardial infarction produced a high early patency rate, significant limitation of infarct size and significant preservation of left ventricular systolic function, mainly in anterior wall infarction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2647817     DOI: 10.1016/0735-1097(89)90249-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  9 in total

1.  Thrombolytic therapy for acute myocardial infarction. Lessons to be learned.

Authors:  S Sherry
Journal:  Tex Heart Inst J       Date:  1991

Review 2.  Late potentials as predictors of risk after thrombolytic treatment?

Authors:  G Breithardt; M Borggrefe; U Karbenn
Journal:  Br Heart J       Date:  1990-09

3.  Is thrombolytic therapy in acute inferior myocardial infarction really better than conventional treatment?

Authors:  T J Tobé
Journal:  Br Heart J       Date:  1995-02

4.  Is thrombolytic therapy really better than conventional treatment in acute inferior myocardial infarction?

Authors:  H S Lee
Journal:  Br Heart J       Date:  1995-10

Review 5.  Cardiovascular therapies in the 1990s. An overview.

Authors:  R C Becker; J M Gore
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

6.  Free radical activity and left ventricular function after thrombolysis for acute infarction.

Authors:  S W Davies; K Ranjadayalan; D G Wickens; T L Dormandy; V Umachandran; A D Timmis
Journal:  Br Heart J       Date:  1993-02

Review 7.  Comparative tolerability profiles of thrombolytic agents. A review.

Authors:  K S Woo; H D White
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

8.  Pre-dosing antibody levels and efficacy of thrombolytic drugs containing streptokinase.

Authors:  J D Gemmill; K J Hogg; F G Dunn; A P Rae; W S Hillis
Journal:  Br Heart J       Date:  1994-09

9.  Community hospital experience with recombinant tissue plasminogen activator in acute myocardial infarction.

Authors:  S M Austin; M Caro; D Gemmel
Journal:  J Gen Intern Med       Date:  1992 Mar-Apr       Impact factor: 5.128

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.